Photograph: James Glossop for The Times Sakuntala Shlwakoti vaccinates a chicken against Newcastle disease using an eye-drop in the village of Khundunabayi Gabesha Chowk in Jhapa, Nepal. In the country, an Edinburgh-based charity backed by the Bill & Melinda Gates Foundation, works to improve animal health and consequently human lives through animal disease vaccination programmes. Specifically, they target Newcastle Disease, which blights backyard poultry, killing 90%+ of the flock year after year. April 2014.
The global Newcastle Disease Vaccine market size is set for rapid growth over the forecast period. In terms of revenue, the global Newcastle Disease Vaccine market accounted for USD 343.9 Million in 2022 and is expected to reach USD 462.6 Million by 2030, growing at a CAGR of 4.3% during the forecast period.
➤ The industry’s expansion is being driven by the growing necessity to manage disease outbreaks.
The global Newcastle disease vaccine market is primarily driven by the rising demand for food items associated with poultry and the raising of vaccines to prevent avian disease outbreaks. Furthermore, the market is being stimulated by the increasing consumption of livestock, the increasing awareness of animal vaccination among veterinary practitioners, and the escalating government food safety initiatives. For instance, the Qatar government established central food laboratories in April 2019 with a variety of food safety procedures and analyses to guarantee that consumers receive high-quality, healthy, and contamination-free meat products, as reported by the Middle East Rating Agency.
➤ The market growth may be limited by the high cost of vaccine development and the limited availability of trained professionals.
The global Newcastle Disease Vaccine Market is confronted with numerous constraints that could impede its expansion in the years ahead. The high cost of vaccine development is one of the primary constraints, which may deter new participants from entering the market. The approval and commercialization of novel vaccines can be delayed by the stringent regulations that govern the development, production, and distribution of vaccines, which is another significant constraint.
➤ The market growth may be limited by the high cost of vaccine development and the limited availability of trained professionals.
The Newcastle disease vaccine industry presents a variety of opportunities that have the potential to stimulate its development in the years ahead. The global demand for safe and effective vaccines is being driven by the increasing prevalence of Newcastle disease in poultry, which is one of the main opportunities. Another significant opportunity is the increasing recognition of the advantages of vaccination among poultry producers, veterinarians, and farmers, which is resulting in a greater acceptance of Newcastle disease vaccines. Furthermore, it is anticipated that the market will be further stimulated by the introduction of new and advanced vaccines that provide enhanced safety, efficacy, and convenience.
➤ The emergence of new strains and the limited access to new, enhanced vaccines may pose a challenge.
The Newcastle disease vaccine industry is confronted with a number of obstacles that could impede its growth and development in the years ahead. The emergence of new and more virulent strains of the Newcastle disease virus is one of the main challenges. This situation could potentially render existing vaccines ineffective and increase the demand for more advanced and effective vaccines. Another significant obstacle is the restricted availability of vaccines in specific regions, particularly in developing countries with inadequate infrastructure and resources.
• Elanco Animal Health, an American pharmaceutical company, announced in 2021 that it had successfully acquired Kindred Biosciences, a biopharmaceutical company that specializes in the development of vaccines for livestock and pets. Kindred’s Newcastle Disease Virus Vectored vaccine platform was acquired as part of the transaction. This platform employs a viral vector to deliver antigens to animals and elicit an immune response.
• Merial Animal Health, a multinational animal health concern, announced in 2020 that it had received approval from the European Medicines Agency for a new inactivated vaccine, Vaxxitek® ND-IBD). The vaccine offers protection against Newcastle Disease and Infectious Bursal Disease in poultry, and its innovative formulation minimizes the likelihood of vaccine reactions.
➤ North America is expected to dominate the global market in terms of market share.
North America has maintained its dominance in the global Newcastle disease vaccine market, which is anticipated to continue throughout the forecast period, as a result of the high incidence of avian diseases, consumer perception of food safety, and the increased consumption of poultry-related food items. Furthermore, the region’s dominance has been significantly influenced by the rapid expansion of poultry flesh production. The United States is the world’s largest producer of poultry flesh, contributing 18.0 percent of the total production, as per the United Nations Food and Agriculture Organization (UNFAO).
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database.
Contact Us:
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714 USA/Canada Toll-Free No.1-855-465-4651
Email: [email protected]
Website: https://www.zionmarketresearch.com
Be First to Comment